A clinical review of the t:slim X2 insulin pump

ABSTRACT Insulin pumps are commonly used for intensive insulin therapy to treat type 1 diabetes in adults and youth. Insulin pump technologies have advanced dramatically in the last several years to integrate with continuous glucose monitors (CGM) and incorporate control algorithms. These control algorithms automate some insulin delivery in response to the glucose information received from the CGM to reduce the occurrence of hypoglycemia and hyperglycemia and improve overall glycemic control. The t:slim X2 insulin pump system became commercially available in 2016. It is an innovative insulin pump technology that can be updated remotely by the user to install new software onto the pump device as new technologies become available. Currently, the t:slim X2 pairs with the Dexcom G6 CGM and there are two advanced software options available: Basal-IQ, which is a predictive low glucose suspend (PLGS) technology, and Control-IQ, which is a Hybrid Closed Loop (HCL) technology. This paper will describe the different types of advanced insulin pump technologies, review how the t:slim X2 insulin pump works, and summarize the clinical studies leading to FDA approval and commercialization of the Basal-IQ and Control-IQ technologies.

[1]  Stephen D Patek,et al.  Fully Closed-Loop Multiple Model Probabilistic Predictive Controller Artificial Pancreas Performance in Adolescents and Adults in a Supervised Hotel Setting. , 2018, Diabetes technology & therapeutics.

[2]  Yogish C Kudva,et al.  Clinical review: Hypoglycemia with intensive insulin therapy: a systematic review and meta-analyses of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections. , 2009, The Journal of clinical endocrinology and metabolism.

[3]  H. Szajewska,et al.  Continuous subcutaneous insulin infusion vs. multiple daily injections in children with type 1 diabetes: a systematic review and meta‐analysis of randomized control trials , 2009, Pediatric diabetes.

[4]  Gregory P. Forlenza,et al.  A Clinical Guide to Advanced Diabetes Devices and Closed-Loop Systems Using the CARES Paradigm. , 2019, Diabetes technology & therapeutics.

[5]  J. Weissberg-Benchell,et al.  Insulin pump therapy: a meta-analysis. , 2003, Diabetes care.

[6]  Bruce A Buckingham,et al.  Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial , 2017, The Lancet.

[7]  Lauren M. Huyett,et al.  Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions , 2020, Diabetes technology & therapeutics.

[8]  David M Maahs,et al.  State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018. , 2019, Diabetes technology & therapeutics.

[9]  David C Klonoff,et al.  Smart Pens Will Improve Insulin Therapy , 2018, Journal of Diabetes Science and Technology.

[10]  Lauren M. Huyett,et al.  Performance of the Omnipod Personalized Model Predictive Control Algorithm with Meal Bolus Challenges in Adults with Type 1 Diabetes , 2018, Diabetes technology & therapeutics.

[11]  D. Klonoff,et al.  Threshold-based insulin-pump interruption for reduction of hypoglycemia. , 2013, The New England journal of medicine.

[12]  R. Hanås,et al.  Continued improvement of metabolic control in Swedish pediatric diabetes care , 2018, Pediatric diabetes.

[13]  D. Maahs,et al.  Frequency of Morning Ketosis After Overnight Insulin Suspension Using an Automated Nocturnal Predictive Low Glucose Suspend System , 2014, Diabetes Care.

[14]  Bruce W Bode,et al.  Consensus Statement by the American Association of Clinical Endocrinologists/American College of Endocrinology insulin pump management task force. , 2014, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[15]  Darrell M. Wilson,et al.  A Randomized Trial of a Home System to Reduce Nocturnal Hypoglycemia in Type 1 Diabetes , 2014, Diabetes Care.

[16]  G. Charpentier,et al.  Customization of home closed-loop insulin delivery in adult patients with type 1 diabetes, assisted with structured remote monitoring: the pilot WP7 Diabeloop study , 2018, Acta Diabetologica.

[17]  C. Cobelli,et al.  In Silico Preclinical Trials: A Proof of Concept in Closed-Loop Control of Type 1 Diabetes , 2009, Journal of diabetes science and technology.

[18]  Howard C. Zisser,et al.  Feasibility of Outpatient Fully Integrated Closed-Loop Control , 2013, Diabetes Care.

[19]  Dana Lewis,et al.  History and Perspective on DIY Closed Looping , 2018, Journal of diabetes science and technology.

[20]  Grant J. Smith,et al.  Real‐world outcomes of insulin pump compared to injection therapy in a population‐based sample of children with type 1 diabetes , 2018, Pediatric diabetes.

[21]  Marc D. Breton,et al.  Closed-Loop Control During Intense Prolonged Outdoor Exercise in Adolescents With Type 1 Diabetes: The Artificial Pancreas Ski Study , 2017, Diabetes Care.

[22]  I. Dicembrini,et al.  Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials , 2019, Acta Diabetologica.

[23]  Gregory P. Forlenza,et al.  In-Clinic Evaluation of the MiniMed 670G System "Suspend Before Low" Feature in Children with Type 1 Diabetes. , 2018, Diabetes technology & therapeutics.

[24]  M. Rickels,et al.  The Transatlantic HbA1c gap: differences in glycaemic control across the lifespan between people included in the US T1D Exchange Registry and those included in the German/Austrian DPV registry , 2020, Diabetic medicine : a journal of the British Diabetic Association.

[25]  S. Dagogo-Jack,et al.  Hypoglycemia in Patients with Type 1 Diabetes: Epidemiology, Pathogenesis, and Prevention , 2013, Current Diabetes Reports.

[26]  Bruce W Bode,et al.  Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes. , 2016, JAMA.

[27]  R. Hovorka,et al.  Automated Insulin Delivery in Adults. , 2020, Endocrinology and metabolism clinics of North America.

[28]  Daniel Howsmon,et al.  Closed-Loop Control Without Meal Announcement in Type 1 Diabetes. , 2017, Diabetes technology & therapeutics.

[29]  R. Beck,et al.  Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials , 2018, Diabetes Care.

[30]  H. Zisser,et al.  Efficacy of the Omnipod Insulin Management System on Glycemic Control in Patients With Type 1 Diabetes Previously Treated With Multiple Daily Injections or Continuous Subcutaneous Insulin Infusion , 2016, Journal of diabetes science and technology.

[31]  WeimerJames,et al.  Physiology-Invariant Meal Detection for Type 1 Diabetes. , 2016 .

[32]  B. Buckingham,et al.  Fast-Acting Insulin Aspart Use with the MiniMed™ 670G System. , 2020, Diabetes technology & therapeutics.

[33]  M. Freemark,et al.  Insulin pump therapy in toddlers and preschool children with type 1 diabetes mellitus. , 2002, The Journal of pediatrics.

[34]  B. Wayne Bequette,et al.  Predictive Low-Glucose Insulin Suspension Reduces Duration of Nocturnal Hypoglycemia in Children Without Increasing Ketosis , 2015, Diabetes Care.

[35]  LazaroCaterina,et al.  Automatic Detection and Estimation of Unannounced Meals for Multivariable Artificial Pancreas System , 2018 .

[36]  B. Zinman,et al.  Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baseline A1c. , 2004, Diabetes care.

[37]  Darrell M. Wilson,et al.  Outpatient safety assessment of an in-home predictive low-glucose suspend system with type 1 diabetes subjects at elevated risk of nocturnal hypoglycemia. , 2013, Diabetes technology & therapeutics.

[38]  Eyal Dassau,et al.  Pilot Studies of Wearable Outpatient Artificial Pancreas in Type 1 Diabetes , 2012, Diabetes Care.

[39]  Martin Holder,et al.  Prevention of hypoglycemia by using low glucose suspend function in sensor-augmented pump therapy. , 2011, Diabetes technology & therapeutics.

[40]  B. Zinman,et al.  Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. , 2005, The New England journal of medicine.

[41]  Stuart A Weinzimer,et al.  Effect of Insulin Feedback on Closed-Loop Glucose Control: A Crossover Study , 2012, Journal of diabetes science and technology.

[42]  J. Clements,et al.  Faster Insulin Aspart: A New Bolus Option for Diabetes Mellitus , 2018, Clinical Pharmacokinetics.

[43]  Marc D. Breton,et al.  Modular Closed-Loop Control of Diabetes , 2012, IEEE Transactions on Biomedical Engineering.

[44]  F. Doyle,et al.  Prevention of Nocturnal Hypoglycemia Using Predictive Alarm Algorithms and Insulin Pump Suspension , 2010, Diabetes Care.

[45]  S. Patek,et al.  Closed-Loop Artificial Pancreas Using Subcutaneous Glucose Sensing and Insulin Delivery and a Model Predictive Control Algorithm: The Virginia Experience , 2009, Journal of diabetes science and technology.

[46]  Eyal Dassau,et al.  Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. , 2019, The New England journal of medicine.

[47]  K. Nørgaard,et al.  Cost‐effectiveness of continuous subcutaneous insulin infusion versus multiple daily injections of insulin in Type 1 diabetes: a systematic review , 2015, Diabetic medicine : a journal of the British Diabetic Association.

[48]  B. Buckingham,et al.  Closed loop control in adolescents and children during winter sports: Use of the Tandem Control‐IQ AP system , 2019, Pediatric diabetes.

[49]  B. Frier.  Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications , 2014, Nature Reviews Endocrinology.

[50]  Benyamin Grosman,et al.  Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes , 2017, Diabetes technology & therapeutics.

[51]  Björn Eliasson,et al.  The National Diabetes Register in Sweden: an implementation of the St. Vincent Declaration for Quality Improvement in Diabetes Care. , 2003, Diabetes care.

[52]  Laya Ekhlaspour,et al.  Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial. , 2016, The lancet. Diabetes & endocrinology.

[53]  Janet M. Allen,et al.  Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial , 2018, The Lancet.

[54]  Eyal Dassau,et al.  Control to Range for Diabetes: Functionality and Modular Architecture , 2009, Journal of diabetes science and technology.

[55]  Lauren M. Huyett,et al.  Performance of Omnipod Personalized Model Predictive Control Algorithm with Moderate Intensity Exercise in Adults with Type 1 Diabetes , 2019, Diabetes technology & therapeutics.

[56]  A. Rawshani,et al.  Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18 168 people with type 1 diabetes: observational study , 2015, BMJ : British Medical Journal.

[57]  Moshe Phillip,et al.  Artificial pancreas: fuzzy logic and control of glycemia , 2014, Current opinion in endocrinology, diabetes, and obesity.

[58]  E. Bass,et al.  Comparative Effectiveness and Safety of Methods of Insulin Delivery and Glucose Monitoring for Diabetes Mellitus , 2012, Annals of Internal Medicine.

[59]  J. Smith-Palmer,et al.  Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes. , 2019, Diabetes technology & therapeutics.

[60]  R. Hovorka,et al.  Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis , 2018, British Medical Journal.

[61]  Lauren M. Huyett,et al.  Closed-Loop Artificial Pancreas Systems: Engineering the Algorithms , 2014, Diabetes Care.

[62]  F. Doyle,et al.  Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range , 2019, Diabetes Care.

[63]  Gregory P. Forlenza,et al.  Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial , 2018, Diabetes Care.

[64]  Lauren M. Huyett,et al.  Novel Bluetooth-Enabled Tubeless Insulin Pump: Innovating Pump Therapy for Patients in the Digital Age , 2018, Journal of diabetes science and technology.

[65]  Josep Vehí,et al.  Unannounced Meals in the Artificial Pancreas: Detection Using Continuous Glucose Monitoring , 2018, Sensors.

[66]  Eyal Dassau,et al.  Outpatient Closed-Loop Control with Unannounced Moderate Exercise in Adolescents Using Zone Model Predictive Control. , 2017, Diabetes technology & therapeutics.

[67]  E. Cengiz.  Automated Insulin Delivery in Children with Type 1 Diabetes. , 2020, Endocrinology and metabolism clinics of North America.

[68]  C. Mameli,et al.  A 7-year follow-up retrospective, international, multicenter study of insulin pump therapy in children and adolescents with type 1 diabetes , 2014, Acta Diabetologica.

[69]  Stephanie Guerlain,et al.  DiAs User Interface: A Patient-Centric Interface for Mobile Artificial Pancreas Systems , 2013, Journal of diabetes science and technology.

[70]  B. Kovatchev,et al.  First Look at Control-IQ: A New-Generation Automated Insulin Delivery System , 2018, Diabetes Care.

[71]  B. Buckingham,et al.  Safety Evaluation of the MiniMed 670G System in Children 7–13 Years of Age with Type 1 Diabetes , 2019, Diabetes technology & therapeutics.